Nutriband faces a precarious financial outlook characterized by volatile revenue streams and a structural inability to achieve profitability, as evidenced by a TTM operating margin of -408.41%.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53.
Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband's AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure.
Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company's listing on the Nasdaq Capital Market, which took effect on October 1, 2021.
Nutriband (NASDAQ: NTRB - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Profitability This table compares Nutriband and ARS Pharmaceuticals'
Benchmark NTRB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nutriband Inc. (NTRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.55 | $67.47M | -9.69 | -4.83% | -430.43% | -109.02% | — | |
| $0.64 | $9.51M | -0.87 | 10429.36% | -804.37% | -748.08% | — | |
| $16.65 | $693.1M | 30.15 | 6.85% | 1.9% | 3.43% | — | |
| $1.25 | $15.29M | -0.68 | — | — | -165.71% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $1.57 | $9.11M | -1.39 | -82.35% | -249.16% | -46.52% | — |
Nutriband Inc. (NTRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nutriband Inc. (NTRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 22, 2026·SEC
Apr 7, 2026·SEC
Feb 13, 2026·SEC
Get notified when NTRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nutriband Inc. (NTRB) stock FAQ — growth, dividends, profitability & financials explained
Nutriband Inc. (NTRB) reported $1.6M in revenue over the trailing twelve months. Revenue was $2.0M in fiscal year 2025.
Nutriband Inc. (NTRB) revenue fell by 37.3% over the trailing twelve months, compared with the twelve months before.
No. Nutriband Inc. (NTRB) reported a net loss of $7.0M over the trailing twelve months.
Nutriband Inc. (NTRB) had a return on equity (ROE) of -109.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Nutriband Inc. (NTRB) had negative free cash flow of $3.6M over the trailing twelve months.
